Inhibitor development in two cousins receiving full-length factor VIII (FVIII) and FVIII-Fc fusion protein

被引：9
作者：
Ragni, M. V. [1 ,2 ]
Alabek, M. [2 ]
Malec, L. M. [2 ,3 ]
机构：
[1] Univ Pittsburgh, Div Hematol Oncol, Pittsburgh, PA USA
[2] Hemophilia Ctr Western Penn, 3636 Blvd Allies, Pittsburgh, PA 15213 USA
[3] Univ Pittsburgh, Childrens Hosp Pittsburgh, Div Pediat Hematol, Pittsburgh, PA 15213 USA
来源：
HAEMOPHILIA | 2016年 / 22卷 / 05期
关键词：
HEMOPHILIA-A; DANGER;
D O I：
10.1111/hae.13032
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E462 / E464
页数：3
相关论文
共 10 条
  • [1] Astermark J, 2005, HAEMATOLOGICA, V90, P924
  • [2] Activation of natural regulatory T cells by IgG Fc-derived peptide "Tregitopes"
    De Groot, Anne S.
    Moise, Leonard
    McMurry, Julie A.
    Wambre, Erik
    Van Overtvelt, Laurence
    Moingeon, Philippe
    Scott, David W.
    Martin, William
    [J]. BLOOD, 2008, 112 (08) : 3303 - 3311
  • [3] Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study
    Gouw, Samantha C.
    van den Berg, H. Marijke
    Fischer, Kathelijn
    Auerswald, Guenter
    Carcao, Manuel
    Chalmers, Elizabeth
    Chambost, Herve
    Kurnik, Karin
    Liesner, Ri
    Petrini, Pia
    Platokouki, Helen
    Altisent, Carmen
    Oldenburg, Johannes
    Nolan, Beatrice
    Perez Garrido, Rosario
    Mancuso, M. Elisa
    Rafowicz, Anne
    Williams, Mike
    Clausen, Niels
    Middelburg, Rutger A.
    Ljung, Rolf
    van der Bom, Johanna G.
    [J]. BLOOD, 2013, 121 (20) : 4046 - 4055
  • [4] The principal results of the International Immune Tolerance Study: a randomized dose comparison
    Hay, Charles R. M.
    DiMichele, Donna M.
    [J]. BLOOD, 2012, 119 (06) : 1335 - 1344
  • [5] Liu T, 2012, HAEMOPHILIA, V18, P41
  • [6] Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A
    Mahlangu, Johnny
    Powell, Jerry S.
    Ragni, Margaret V.
    Chowdary, Pratima
    Josephson, Neil C.
    Pabinger, Ingrid
    Hanabusa, Hideji
    Gupta, Naresh
    Kulkarni, Roshni
    Fogarty, Patrick
    Perry, David
    Shapiro, Amy
    Pasi, K. John
    Apte, Shashikant
    Nestorov, Ivan
    Jiang, Haiyan
    Li, Shuanglian
    Neelakantan, Srividya
    Cristiano, Lynda M.
    Goyal, Jaya
    Sommer, Jurg M.
    Dumont, Jennifer A.
    Dodd, Nigel
    Nugent, Karen
    Vigliani, Gloria
    Luk, Alvin
    Brennan, Aoife
    Pierce, Glenn F.
    [J]. BLOOD, 2014, 123 (03) : 317 - 325
  • [7] The danger model: A renewed sense of self
    Matzinger, P
    [J]. SCIENCE, 2002, 296 (5566) : 301 - 305
  • [8] Biochemical and functional characterization of a recombinant monomeric factor VIII-Fc fusion protein
    Peters, R. T.
    Toby, G.
    Lu, Q.
    Liu, T.
    Kulman, J. D.
    Low, S. C.
    Bitonti, A. J.
    Pierce, G. F.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 (01) : 132 - 141
  • [9] Design of the INHIBIT trial: preventing inhibitors by avoiding 'danger', prolonging half-life and promoting tolerance
    Ragni, Margaret V.
    Malec, Lynn M.
    [J]. EXPERT REVIEW OF HEMATOLOGY, 2014, 7 (06) : 747 - 755
  • [10] DISAPPEARANCE OF INHIBITOR TO FACTOR-VIII IN HIV-INFECTED HEMOPHILIACS WITH PROGRESSION TO AIDS OR SEVERE ARC
    RAGNI, MV
    BONTEMPO, FA
    LEWIS, JH
    [J]. TRANSFUSION, 1989, 29 (05) : 447 - 449
1